ICU Medical (NASDAQ:ICUI) Releases Earnings Results, Beats Expectations By $0.46 EPS

Key Points

• ICU Medical exceeded quarterly expectations: Adjusted EPS came in at $2.37 versus the $1.91 consensus, while revenue reached $547.9 million compared with estimates of $533.4 million. Organic revenue grew 6%, led by record sales in Infusion Systems and Consumables.
• Management raised its 2026 outlook: Adjusted EPS guidance is now $8.60–$9.00 and adjusted EBITDA guidance is $415–$435 million, alongside an expected gross margin of approximately 41.5%.
• Risks remain despite the strong results: Tariffs, unfavorable currency movements and higher fuel costs are pressuring the outlook, while Vital Care sales declined 4% organically and product-development timelines remain uncertain.

ICU Medical (NASDAQ:ICUI - Get Free Report) announced its quarterly earnings data on Thursday. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.91 by $0.46, FiscalAI reports. ICU Medical had a net margin of 1.39% and a return on equity of 7.94%. The firm had revenue of $547.88 million during the quarter, compared to analyst estimates of $533.44 million. During the same quarter in the prior year, the firm posted $2.10 earnings per share. ICU Medical's quarterly revenue was up .5% on a year-over-year basis. ICU Medical updated its FY 2026 guidance to 8.600-9.000 EPS.

Here are the key takeaways from ICU Medical's conference call:

• Second-quarter results exceeded expectations on earnings momentum, with organic revenue growth of 6%, adjusted EBITDA up 10% to $110 million, and adjusted EPS up 13% to $2.37.
• ICU Medical raised and narrowed its 2026 adjusted EBITDA guidance to $415 million–$435 million and adjusted EPS guidance to $8.60–$9.00, while increasing expected full-year adjusted gross margin to approximately 41.5%.
• Infusion Systems and Consumables delivered record sales, growing 12% and 5% organically, respectively. Management expects Systems organic growth at or above 6% in the near term and continued mid-single-digit growth in Consumables.
• Strong free cash flow of $62 million, including a $20 million tariff refund, enabled $50 million of debt repayment and reduced net leverage to 2.3 times; management remains on track for approximately 2 times leverage by year-end.
• The outlook still faces pressure from tariffs, unfavorable currencies, and higher oil and diesel costs, while Vital Care declined 4% organically and is expected to remain slightly down for the full year. Some pump installations occurred earlier than expected, and the timing of Medfusion 5000 FDA resubmission and CAD development remains uncertain.

ICU Medical Stock Up 10.9%

Shares of ICUI traded up $18.19 during mid-day trading on Friday, hitting $184.56. 931,233 shares of the company's stock were exchanged, compared to its average volume of 304,941. The company has a market cap of $4.61 billion, a price-to-earnings ratio of 156.41, a P/E/G ratio of 2.58 and a beta of 0.74. ICU Medical has a fifty-two week low of $107.00 and a fifty-two week high of $192.85. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34. The stock's 50-day moving average is $151.64 and its 200-day moving average is $141.02.

Key Stories Impacting ICU Medical

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: Quarterly earnings beat expectations: ICU Medical reported second-quarter adjusted EPS of $2.37, up from $2.10 a year earlier and well above the $1.91 analyst consensus. Revenue reached $547.9 million versus expectations of $533.4 million, with infusion systems cited as a key growth driver. ICU Medical Q2 results beat analyst expectations, driven by infusion systems
• Positive Sentiment: Higher 2026 earnings outlook: The company raised or updated fiscal 2026 EPS guidance to $8.60–$9.00, above the approximately $7.83 consensus estimate. This indicates management expects stronger profitability than Wall Street previously modeled. ICU Medical Announces Second Quarter 2026 Results and Updates its Fiscal Year 2026 Guidance
• Positive Sentiment: Analysts raised price targets: Piper Sandler increased its target from $163 to $195 and maintained an “overweight” rating. Needham raised its target from $165 to $187 and reiterated a “buy” rating. The revisions reinforce the view that the earnings beat and guidance update improve ICU Medical’s growth outlook. ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings
• Neutral Sentiment: Valuation remains demanding: Despite the favorable earnings news, ICU Medical trades at a high earnings multiple, meaning further gains may depend on the company delivering against its elevated guidance and sustaining growth.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on ICUI shares. Needham & Company LLC boosted their target price on shares of ICU Medical from $165.00 to $187.00 and gave the company a "buy" rating in a report on Friday. Piper Sandler raised their price target on shares of ICU Medical from $163.00 to $195.00 and gave the stock an "overweight" rating in a report on Friday. Jefferies Financial Group upgraded ICU Medical to a "strong-buy" rating in a report on Thursday, May 7th. Zacks Research lowered ICU Medical from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 28th. Finally, Weiss Ratings raised ICU Medical from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Thursday, July 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, ICU Medical currently has an average rating of "Moderate Buy" and a consensus target price of $192.80.

Insider Buying and Selling

In other ICU Medical news, VP Virginia Ruth Sanzone sold 2,447 shares of the firm's stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total value of $303,623.76. Following the completion of the transaction, the vice president owned 19,460 shares of the company's stock, valued at $2,414,596.80. This trade represents a 11.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director David C. Greenberg sold 2,424 shares of the firm's stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total transaction of $297,933.84. Following the completion of the transaction, the director directly owned 7,960 shares of the company's stock, valued at $978,363.60. This represents a 23.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 2.10% of the company's stock.

Institutional Trading of ICU Medical

Several hedge funds have recently modified their holdings of ICUI. Smartleaf Asset Management LLC increased its holdings in ICU Medical by 11.6% during the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier's stock worth $128,000 after purchasing an additional 101 shares during the period. Headlands Technologies LLC purchased a new position in shares of ICU Medical in the 2nd quarter valued at about $177,000. O Shaughnessy Asset Management LLC purchased a new position in shares of ICU Medical in the 4th quarter valued at about $203,000. Panagora Asset Management Inc. acquired a new position in shares of ICU Medical during the fourth quarter worth about $205,000. Finally, Janney Montgomery Scott LLC acquired a new position in shares of ICU Medical during the fourth quarter worth about $216,000. 96.10% of the stock is currently owned by institutional investors and hedge funds.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source